Study of Parenterally Administrated Adjuvanted Seasonal Influenza Vaccine in Healthy Elderly Volunteers

NCT01444482 | Unknown Phase 1

• 1 other identifier: ISC-Influenza-001
• Study Type: interventional
• Target: 110
• Locations: 1 country
• Sites: 1

Brief Summary

The safety of parenterally administrated investigational vaccine (commercial influenza vaccine formulated with adjuvant Matrix M) in healthy adults (age 18-50) and healthy elderly (age 65-75), will be investigated in the study. Moreover, the study aims to study parameters associated with improved protection against clinical disease in elderly. Such parameters include HI-titres, a balanced Th1/Th2 response as well as a functional cellular immune response. Vaccination will start in 22 healthy adults receiving the investigational vaccine. Vaccination of elderly will be initiated only after demonstration of safety in adults. 88 healthy elderly volunteers will be vaccinated, 44 will receive the seasonal influenza vaccine alone and 44 will receive the investigational vaccine. Vaccines will be administrated intramuscularly in the upper arm. One dose will be administered to each volunteer included in the study. Blood samples for basic immunological assessments of cellular and humoral immunity will be taken at day 0, 7, 28, 90 and 150. The investigational vaccine is equal to one standard human dose of a commercial seasonal influenza vaccine to which 50 µg of adjuvant Matrix M has been added.

Conditions

Influenza

Outcome Measures

Primary Outcomes (1)

• Safety in elderly and adults given a single parenterally administrated dose of seasonal influenza vaccine adjuvanted with Matrix M

  1 - 3 months

Secondary Outcomes (2)

• Immunogenicity in adults and elderly given a dose of seasonal influenza vaccine adjuvanted with Matrix M

  1 - 7 months

• Immunogenicity in elderly given a dose of seasonal influenza vaccine alone or adjuvanted with Matrix M

  1 - 7 months

Study Arms (2)

Matrix M adjuvanted influenza vaccine

EXPERIMENTAL

1 human dose of seasonal influenza vaccine formulated with 50 µg Matrix M

Biological: Matrix M

Seasonal influenza vaccine

ACTIVE COMPARATOR

1 human dose of seasonal influenza vaccine

Biological: Seasonal influenza vaccine

Interventions

Matrix M BIOLOGICAL

1 human dose of seasonal influenza vaccine formulated with 50 µg Matrix M, total dosage volume 0.55 mL injected intramuscularly in the upper arm once at day 0.

Matrix M adjuvanted influenza vaccine

Seasonal influenza vaccine BIOLOGICAL

1 human dose of seasonal influenza vaccine

Seasonal influenza vaccine

Eligibility Criteria

• Age: 65 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Older Adult (65+)

You may qualify if:

• Are aged 18 to 50 years for the young adult part of the study
• Are aged 65 to 75 years for main study
• Have signed a voluntary written informed consent. Volunteers should be cooperative, willing and able to participate and adhere to the Protocol requirements
• Have minimum normal standard physical performance status

You may not qualify if:

• Volunteer has received seasonal Influenza vaccine of same antigenic composition within 6 months prior to enrolment
• Volunteer having vaccine specific HI titres ≥ 40
• Volunteer is taking immunosuppressant drugs such as azathioprine, tacrolimus, cyclosporine, etc
• Volunteers who have primary or secondary immunodeficiencies (e.g. Human Immunodeficiency Virus \[HIV\])
• Volunteers who have an autoimmune disease
• Volunteer is taking oral, intramuscular or intravenous corticosteroids. Use is not permitted within 1 month of Screening. Inhaled corticosteroids to treat respiratory insufficiency (e.g. chronic obstructive pulmonary disease \[COPD\]), are permitted
• Volunteer has a concurrent severe or uncontrolled underlying medical disease unrelated but that is likely to compromise volunteer safety and affect the outcome of the study
• Volunteer has a neurotoxicity (Grade ≥2)
• Volunteer has diarrhoea (Grade ≥2)
• Volunteer has received other vaccines, within 1 month prior to enrolment
• Volunteer has a history of any severe or life-threatening hypersensitivity reaction
• Volunteer has an unstable systemic disease (including active infection, uncontrolled hypertension \[\> 160/100\], unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal and metabolic disease)
• Volunteer has recent history (within 6 months) of chronic alcohol or drug abuse of which may compromise the patient's safety or ability to participate in study activities
• Volunteer has a history of psychiatric disorder that prevents patients from providing informed consent or following Protocol instructions
• Volunteer is currently enrolled in an investigational device or drug trial, or \< 1 month since completing an investigational device or drug trial

Sponsors & Collaborators

• Isconova AB: lead

Study Sites (1)

Drug Reseach Center

Balatonfüred, Balatonfured, 8231, Hungary

Location

MeSH Terms

Conditions

Influenza, Human

Interventions

Matrix-M

Condition Hierarchy (Ancestors)

Respiratory Tract Infections; Infections; Orthomyxoviridae Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 19, 2011
• First Posted: September 30, 2011
• Study Start: May 1, 2011
• Primary Completion: November 1, 2011
• Last Updated: September 30, 2011

Record last verified: 2011-09

Locations

HU (1)